Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world

Aaron Logan, Fevzi Yalniz, Amy Zhang, Katharine Miller, Katherine Sutherland, Nikeshan Jeyakumar, Hrishikesh Srinagesh, Michael Grunwald, Vamsi Kota, Jacob Boccucci, Matthew Ulrickson, Ali Al-Darobi, Joshua Sasine, LaQuisa Hill, Ibrahim Muhsen, Anjali Advani, Ibrahim Aldoss, Tamer Othman, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Evan Chen, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Catherine Lee, Silvina Odstrcil Bobillo, Stephanie Tsai, Timothy O'Connor, Talal Hilal, Jae Park, Yannis Valtis, Sumithira Vasu, Evandro Bezerra, Eunice Wang, Jessica Leonard, Virginia Tan, Kristen O'Dwyer, Jozal Moore, Ross McCauley, Navneet Majhail, Luke Mountjoy, Aravind Ramakrishnan, Shahbaz Malik, Minoo Battiwalla, Paul Shaughnessy, John Mathews, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Wendy Stock, Gregory Roloff, Caspian Oliai, Georgia Lill, Marc Schwartz, Divya Koura, Kaitlyn Dykes, Michael Daunov, Ken Byrd, Veronika Bachanova, Sean Tracy, Punita Grover, Noelle Frey, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Rawan Faramand, Lori Muffly

Blood (2025) 146 (Supplement 1): 516.

https://doi.org/10.1182/blood-2025-516

Published: 2025

Journal Articles

Efficacy of frontline fixed duration chemotherapy in MAPK-pathway altered adult langerhans cell histiocytosis: A multi-institutional international retrospective study

Blood (2025) 146 (Supplement 1): 2999.

https://doi.org/10.1182/blood-2025-2999

Published: 2025

Journal Articles

Real-world treatment patterns and survival outcomes in primary CNS lymphoma: Analysis of the national cancer database

Ayo Falade, Yu Tao, Olisaemeka Ogbue, Oluwatayo Adeoye, Ayodeji Johnson, Arushi Khurana, Jithma Abeykoon, Urshila Durani, Mazie Tsang, Allison Rosenthal, Talal Hilal, Javier Munoz, Patrick Johnston, Han Tun, Grzegorz Nowakowski, James Cerhan, Richard Godby, Yucai Wang, Jihao Zhou

Blood (2025) 146 (Supplement 1): 4494.

https://doi.org/10.1182/blood-2025-4494

Published: 2025

Journal Articles

CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel

Ross McCauley, Amy Zhang, Vamsi Kota, Jacob Boccucci, Michael Grunwald, Matthew Ulrickson, LaQuisa Hill, Ibrahim Muhsen, Joshua Sasine, Anjali Advani, Ibrahim Aldoss, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Silvina Odstrcil Bobillo, Stephanie Tsai, Talal Hilal, Bijal Shah, Rawan Faramand, Jae Park, Yannis Valtis, Tamer Othman, Sumithira Vasu, Evandro Bezerra, Jessica Leonard, Virginia Tan, Kristen O'Dwyer, Jozal Moore, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Wendy Stock, Caspian Oliai, Georgia Lill, Marc Schwartz, Divya Koura, Kaitlyn Dykes, Aaron Logan, Michael Daunov, Ken Byrd, Fevzi Yalniz, Noelle Frey, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Ali Al-Darobi, Evan Chen, Catherine Lee, Timothy O'Connor, Bhagirathbhai Dholaria, Veronika Bachanova, Sean Tracy, Hrishikesh Srinagesh, Katharine Miller, Katherine Sutherland, Navneet Majhail, Luke Mountjoy, Shahbaz Malik, Aravind Ramakrishnan, Paul Shaughnessy, John Mathews, Eunice Wang, Minoo Battiwalla, Gregory Roloff, Lori Muffly

Blood (2025) 146 (Supplement 1): 2396.

https://doi.org/10.1182/blood-2025-2396

Published: 2025

Journal Articles

Safety and efficacy of post transplant cyclophosphamide vs tacrolimus plus methotrexate for gvhd prophylaxis in myelofibrosis

Usman Ilyas, Carolyn Mead-Harvey, Yenny Moreno Vanegas, Muhammad Abdullah Humayun, Kanishka Uttam Chandani, Diana Zamora Quintanilla, Ernesto Ayala, Saurabh Chhabra, James Foran, Talal Hilal, Madiha Iqbal, Mohamed Kharfan-Dabaja, Nandita Khera, Jose Leis, Hemant Murthy, Nathan Punwani, Vivek Roy, Lisa Sproat, Jeanne Palmer

Blood (2025) 146 (Supplement 1): 6016.

https://doi.org/10.1182/blood-2025-6016

Published: 2025

Journal Articles

Evaluation of outcomes and toxicities of loncastuximab tesirine (Lonca) in relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Real-world data analysis (RWDA) from 10 US academic centers

Blood (2025) 146 (Supplement 1): 4514.

https://doi.org/10.1182/blood-2025-4514

Published: 2025

Journal Articles

Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States

Yun Kyoung Tiger, Roshan Asrani, Graham Wehmeyer, Robert Ryan, Ajay Major, Natalie Grover, Kelsey Baron, Talal Hilal, Adrienne Nedved, Taylor Brooks, Arjun Ravishankar, Tarsheen Sethi, Brian Hill, Yucai Wang, Allison Bock, Adam Kittai, Matthew Matasar, Joanna Rhodes

Blood (2025) 146 (Supplement 1): 1956.

https://doi.org/10.1182/blood-2025-1956

Published: 2025

Journal Articles

KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)

Jessica Leonard, Abdullah Ladha, Rawan Faramand, Gregory Roloff, Yannis Valtis, Virginia Tan, Katharine Miller, Amy Zhang, Michael Grunwald, Vamsi Kota, Jacob Boccucci, Matthew Ulrickson, Ali Al-Darobi, LaQuisa Hill, Ibrahim Muhsen, Joshua Sasine, Anjali Advani, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Evan Chen, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Catherine Lee, Silvina Odstrcil Bobillo, Stephanie Tsai, Timothy O'Connor, Talal Hilal, Jae Park, Sumithira Vasu, Evandro Bezerra, Kristen O'Dwyer, Jozal Moore, Eunice Wang, Ross McCauley, Navneet Majhail, Aravind Ramakrishnan, Luke Mountjoy, Shahbaz Malik, Minoo Battiwalla, Paul Shaughnessy, John Mathews, Hrishikesh Srinagesh, Katherine Sutherland, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Caspian Oliai, Georgia Lill, Wendy Stock, Marc Schwartz, Tamer Othman, Divya Koura, Kaitlyn Dykes, Aaron Logan, Michael Daunov, Ken Byrd, Fevzi Yalniz, Veronika Bachanova, Sean Tracy, Punita Grover, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Noelle Frey, Lori Muffly, Bijal Shah, Ibrahim Aldoss

Blood (2025) 146 (Supplement 1): 3365.

https://doi.org/10.1182/blood-2025-3365

Published: 2025

Journal Articles

KRAS mutations in histiocytic neoplasms: Mutation spectrum and response to MEK inhibition

Blood (2025) 146 (Supplement 1): 6760.

https://doi.org/10.1182/blood-2025-6760

Published: 2025

Journal Articles

Incidence of second primary malignancies (SPMs) following bispecific antibody (BsAb) therapy for lymphoid malignancies: A descriptive analysis of clinical trials

Rodrigo Fonseca, Talal Hilal

Blood (2025) 146 (Supplement 1): 8071.

https://doi.org/10.1182/blood-2025-8071

Published: 2025

Journal Articles

Impact of prior venetoclax use on mortality in CLL patients treated with pirtobrutinib: A propensity-matched cohort study

Kanishka Uttam Chandani, Ritu C. Tated, Sarah Monick, Pragyat Futela, Dhruvi Joshi, Sooraj Srirangadhamu Gopu, Jatin Thukral, Diana Zamora Quintanilla, Apoorva Kondapally, Talal Hilal

Blood (2025) 146 (Supplement 1): 2135.

https://doi.org/10.1182/blood-2025-2135

Published: 2025

Journal Articles

Real-world comparison of CAR T-cell therapy versus bispecific antibodies in relapsed or refractory multiple myeloma

Jia Yi Tan, Aravinthan Vignarajah, Nurliyanah Atiqah, Daniel O'Leary, Talal Hilal

Blood (2025) 146 (Supplement 1): 2799.

https://doi.org/10.1182/blood-2025-2799

Published: 2025

Journal Articles

Evolving insights and changes in survival of erdheim-chester disease over time

Blood (2025) 146 (Supplement 1): 2990.

https://doi.org/10.1182/blood-2025-2990

Published: 2025

Journal Articles

Machine learning–driven prognostication of overall survival at 6 months after CAR-T cell therapy

Blood (2025) 146 (Supplement 1): 2563.

https://doi.org/10.1182/blood-2025-2563

Published: 2025

Journal Articles

Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population

Blood (2025) 146 (Supplement 1): 3905.

https://doi.org/10.1182/blood-2025-3905

Published: 2025

Journal Articles

Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 798.

https://doi.org/10.1182/blood-2025-798

Published: 2025

Journal Articles

Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis

Blood (2025) 146 (Supplement 1): 2715.

https://doi.org/10.1182/blood-2025-2715

Published: 2025

Journal Articles

Real-world one-month mortality and bleeding outcomes with caplacizumab in thrombotic thrombocytopenic purpura: A propensity-matched cohort study

Kanishka Uttam Chandani, Usman Ilyas, Ritu C. Tated, Pragyat Futela, Dhruvi Joshi, Apoorva Kondapally, Jatin Thukral, Sooraj Srirangadhamu Gopu, Donald Northfelt, Surbhi Shah, Theresa Kinard, Lawrence Williams, Mazie Tsang, Talal Hilal

Blood (2025) 146 (Supplement 1): 4892.

https://doi.org/10.1182/blood-2025-4892

Published: 2025

Journal Articles

Axicabtagene ciloleucel versus tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma

Jia Yi Tan, Hermon Wong, Aravinthan Vignarajah, Daniel Ezekwudo, Jon Arnason, Talal Hilal

Blood (2025) 146 (Supplement 1): 6282.

https://doi.org/10.1182/blood-2025-6282

Published: 2025

Journal Articles

Progression of disease within 36 months (POD36) of starting first-line targeted therapy independently predicts poor overall survival in patients with chronic lymphocytic leukemia (CLL)

Blood (2025) 146 (Supplement 1): 5667.

https://doi.org/10.1182/blood-2025-5667

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world

Efficacy of frontline fixed duration chemotherapy in MAPK-pathway altered adult langerhans cell histiocytosis: A multi-institutional international retrospective study

Real-world treatment patterns and survival outcomes in primary CNS lymphoma: Analysis of the national cancer database

CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel

Safety and efficacy of post transplant cyclophosphamide vs tacrolimus plus methotrexate for gvhd prophylaxis in myelofibrosis

Evaluation of outcomes and toxicities of loncastuximab tesirine (Lonca) in relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Real-world data analysis (RWDA) from 10 US academic centers

Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States

KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)

KRAS mutations in histiocytic neoplasms: Mutation spectrum and response to MEK inhibition

Incidence of second primary malignancies (SPMs) following bispecific antibody (BsAb) therapy for lymphoid malignancies: A descriptive analysis of clinical trials

Impact of prior venetoclax use on mortality in CLL patients treated with pirtobrutinib: A propensity-matched cohort study

Real-world comparison of CAR T-cell therapy versus bispecific antibodies in relapsed or refractory multiple myeloma

Evolving insights and changes in survival of erdheim-chester disease over time

Machine learning–driven prognostication of overall survival at 6 months after CAR-T cell therapy

Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population

Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia

Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis

Real-world one-month mortality and bleeding outcomes with caplacizumab in thrombotic thrombocytopenic purpura: A propensity-matched cohort study

Axicabtagene ciloleucel versus tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma

Progression of disease within 36 months (POD36) of starting first-line targeted therapy independently predicts poor overall survival in patients with chronic lymphocytic leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only